Aurora Investment Managers LLC. Purchases Shares of 2,707 Edwards Lifesciences Corporation $EW

Aurora Investment Managers LLC. purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, HoldingsChannel.com reports. The fund purchased 2,707 shares of the medical research company’s stock, valued at approximately $212,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of EW. Arlington Trust Co LLC raised its holdings in shares of Edwards Lifesciences by 1.2% in the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock worth $804,000 after buying an additional 135 shares during the last quarter. Valeo Financial Advisors LLC raised its holdings in shares of Edwards Lifesciences by 2.8% in the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock worth $372,000 after buying an additional 142 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after buying an additional 145 shares during the last quarter. Dakota Wealth Management raised its holdings in shares of Edwards Lifesciences by 2.5% in the second quarter. Dakota Wealth Management now owns 6,048 shares of the medical research company’s stock worth $473,000 after buying an additional 146 shares during the last quarter. Finally, Leo Wealth LLC raised its holdings in shares of Edwards Lifesciences by 1.2% during the first quarter. Leo Wealth LLC now owns 12,488 shares of the medical research company’s stock worth $905,000 after purchasing an additional 150 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Down 1.3%

Shares of NYSE EW opened at $75.75 on Thursday. The company’s 50-day simple moving average is $78.28 and its 200-day simple moving average is $76.05. Edwards Lifesciences Corporation has a 52-week low of $64.89 and a 52-week high of $83.00. The firm has a market cap of $44.47 billion, a price-to-earnings ratio of 10.90, a price-to-earnings-growth ratio of 3.69 and a beta of 1.05. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. Edwards Lifesciences’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on EW shares. The Goldman Sachs Group reissued a “buy” rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Wall Street Zen cut shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday. Morgan Stanley raised their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. Finally, BTIG Research raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a report on Tuesday, July 29th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average price target of $87.06.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.